文献速递区域麻醉与超声疼痛医学

胸肌I阻滞不能改善乳腺癌术后镇痛:随机双盲双中心对照试验

Pectoral I Block Does Not Improve Postoperative Analgesia After Breast Cancer Surgery: A Randomized, Double-Blind, Dual-Centered Controlled Trial.
PubMed 文献 · Reg Anesth Pain Med · 2018-01-01

主要结局为恢复室30分钟或吗啡给药前疼痛评分(NRS≥4/10),结果显示两组无显著差异(3.0 vs 3.0,P=0.55)。结论:在多模式镇痛下,Pecs I不优于生理盐水安慰剂,但在扩大性(大)乳腺手术中的作用可能值得进一步研究。

要点

  • Pecs I阻滞在多模式镇痛基础上未改善乳腺癌术后恢复室疼痛评分。
  • 大手术亚组(乳房切除或肿瘤切除加腋窝清扫)NRS有统计学差异但无临床意义。
  • 大手术亚组恢复室吗啡消耗量Pecs I组较低(1.5 mg vs 6.0 mg,P=0.016)。

核心结论

  • 在多模式镇痛背景下,Pecs I阻滞不优于生理盐水安慰剂用于乳腺癌手术术后镇痛。
  • Pecs I在扩大性(大)乳腺手术中的作用可能值得进一步研究。

研究设计与样本

  • 所有患者采用多模式镇痛方案及术者局部麻醉浸润。
  • 超声引导Pecs I使用布比卡因或生理盐水。
  • 主要结局为恢复室30分钟或吗啡给药前(NRS≥4/10)疼痛评分。
  • 次要结局为恢复室及24小时后阿片类药物消耗量。

主要发现

  • 恢复室NRS在布比卡因组(n=62,3.0 [1.0-4.0])与安慰剂组(n=65,3.0 [1.0-5.0])间无显著差异(P=0.55)。
  • 大手术亚组(n=29)NRS有统计学显著差异但无临床意义:3.0 [0.0-4.0] vs 4.0 [2.0-5.0],P=0.04。
  • 恢复室吗啡消耗量总体无差异(1.5 mg [0.0-6.0 mg] vs 3.0 mg [0.0-6.0 mg],P=0.20)。
  • 大手术亚组恢复室吗啡消耗量有差异:1.5 mg [0.0-6.0 mg] vs 6.0 mg [0.0-12.0 mg],P=0.016。
  • 术中舒芬太尼及24小时累积吗啡消耗量两组无差异;3例患者出现Pecs I相关并发症。

关键数值与推荐

  • 主要结局指标:恢复室30分钟或吗啡给药前NRS≥4/10。
  • 大手术亚组NRS:布比卡因组3.0 [0.0-4.0] vs 安慰剂组4.0 [2.0-5.0],P=0.04。
  • 大手术亚组恢复室吗啡消耗量:1.5 mg [0.0-6.0 mg] vs 6.0 mg [0.0-12.0 mg],P=0.016。

临床怎么用

  • 在多模式镇痛及术者局部麻醉浸润基础上,不应常规期望Pecs I阻滞改善乳腺癌术后镇痛。
  • 对于扩大性(大)乳腺手术,Pecs I可能减少恢复室吗啡消耗,但需进一步研究验证。
  • 实施Pecs I时需注意相关并发症风险。

局限性

  • 大手术亚组样本量较小(n=29),结果需谨慎解读。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: General anesthesia for breast surgery may be supplemented by using a regional anesthetic technique. We evaluated the efficacy of the first pectoral nerve block (Pecs I) in treating postoperative pain after breast cancer surgery. METHODS: A randomized, double-blind, dual-centered, placebo-controlled trial was performed. One hundred twenty-eight patients scheduled for unilateral breast cancer surgery were recruited. A multimodal analgesic regimen and surgeon-administered local anesthetic infiltration were used for all patients. Ultrasound-guided Pecs I was performed using bupivacaine or saline. The primary outcome was the patient pain score (numerical rating scale [NRS]) in the recovery unit 30 minutes after admission or just before the morphine administration (NRS ≥4/10). The secondary outcomes were postoperative opioid consumption (ie, in the recovery unit and after 24 hours). RESULTS: During recovery, no significant difference in NRS was observed between the bupivacaine (n = 62, 3.0 [1.0-4.0]) and placebo (n = 65, 3.0 [1.0-5.0]) groups (P = 0.55). However, the NRS was statistically significantly different, although not clinically significant, for patients undergoing major surgeries (mastectomies or tumorectomies with axillary clearance) (n = 29, 3.0 [0.0-4.0] vs 4.0 [2.0-5.0], P = 0.04). Morphine consumption during recovery did not differ (1.5 mg [0.0-6.0 mg] vs 3.0 mg [0.0-6.0 mg], P = 0.20), except in the major surgery subgroup (1.5 mg [0.0-6.0 mg] vs 6.0 mg [0.0-12.0 mg], P = 0.016). Intraoperative sufentanil and cumulative morphine consumption up to 24 hours did not differ between the 2 groups. Three patients experienced complications related to the Pecs I. CONCLUSIONS: Pecs I is not better than a saline placebo in the presence of multimodal analgesia for breast cancer surgery. However, its role in extended (major) breast surgery may warrant further investigation. CLINICAL TRIAL REGISTRATION: This study was registered at ClinicalTrials.gov, identifier NCT01670448.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Cros J, Sengès P, Kaprelian S, et al. Pectoral I Block Does Not Improve Postoperative Analgesia After Breast Cancer Surgery: A Randomized, Double-Blind, Dual-Centered Controlled Trial. Reg Anesth Pain Med. 2018. PMID: 29672368. doi:10.1097/AAP.0000000000000779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。